Navigation Links
Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes
Date:3/28/2008

DENVER, March 28 /PRNewswire/ -- Long-chain (seafood) omega-3 polyunsaturated fatty acids (PUFAs) continue to prove their value in heart, brain and eye health, according to recent research summarized in the March 2008 Fats of Life and PUFA Newsletter electronic publications. Groundbreaking studies also show that omega-3s may improve recovery from spinal cord injury and dry eye syndrome.

The effect of fish oil consumption on arterial elasticity, which allows for more rapid blood flow, was examined in China in overweight patients with high blood pressure. Participants who took 900 mg of seafood omega-3s daily for eight weeks had a 21% increase in arterial elasticity.

"While blood pressure did not change in these participants, their arterial elasticity significantly improved," said Editor Joyce Nettleton, D.Sc. "This observation suggests another way in which these omega-3s protect heart health."

A US study reported that marine omega-3s prevented atrial fibrillation- uncontrolled rapid trembling -- from developing in animals with fast heartbeats. By increasing the heart's recovery time, the omega-3s prevented abnormal rhythms from becoming established.

Investigators in the Netherlands recently examined the relationship between children's omega-3 status at birth, which depends on the mother's omega-3 intake during pregnancy, and their motor development at age seven. Those with the highest levels of the omega-3 DHA (docosahexaenoic acid) at birth had significantly higher total motor scores than children born with less DHA.

"This means that a mother's consumption of seafood omega-3s during pregnancy is important for her child's later motor development," Nettleton said.

Two other studies covered by the e-newsletters report improvement in mental disorders with dietary seafood omega-3s. Treating substance abuse patients with these omega-3s, mainly EPA (eicosapen-taenoic acid), for example, resulted in significantly lower scores
'/>"/>

SOURCE Fats of Life
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Omega-3s Guard Against Type 1 Diabetes
2. Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s
3. Maine Natural Health Company Brings Omega-3 Benefits to Pets
4. Omega-3s Linked to Prevention of Parkinsons Disease and More
5. Nordic Naturals Professional Exclusive Division Redefines High Potency Omega-3 Supplementation With New Elite Line!
6. Ongoing Tests Show Kona Kampachi(R) is Rich in Omega-3s With No Detectable Mercury
7. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
8. Infant formula must contain DHA omega-3 and AA omega-6, say international experts
9. Diet Change Can Curb Fatty Liver Disease
10. Attenuation of NASH by stimulation of free fatty acid metabolism
11. Drops of Fatty Acid Curb Symptoms of Dry Eye Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...way to fight leukemia might be to knock out a spec..., a new study shows// . The findings suggest tha...ght on its own be an effective therapy. But such... with several existing drugs might also offer an e...
...drink heavily during the college days has an incre..., reports researchers// at the American Heart Asso...s. In a small study, Minnesota researchers found...drank heavily had higher levels of C-reactive prot...
...ave identified a subgroup of hard-to-treat breast ...n, rarely used in the treatment of breast tumors. ... this sensitivity, which may help identify patient.... The findings will be tested in a clinical trial ...
...ell-based therapeutic vaccine for pancreatic cance...rom progressing in a handful of patients three yea...ng evidence that the vaccine can trigger a patient...er and offer new insights into how the vaccine cou...
Other Medicine News:Health News:Knocking Out Survival Protein Could Fight Leukemia 2Health News:Alcohol Abuse During College Days Leads to Heart Disease in Later Life 2Health News:Alcohol Abuse During College Days Leads to Heart Disease in Later Life 3Health News:Researchers Have Identified Subgroup Sensitive to the Drug Cisplatin 2Health News:Vaccine for Pancreatic Cancer Halts Progression of Disease in Some Patients 2
(Date:9/4/2008)...ctivity and favorable safety ...Newswire-FirstCall/ -- Idenix,Pharmaceuticals, Inc...gaged,in the discovery and development of drugs fo...s diseases, today announced that it has completed ...n-nucleoside reverse,transcriptase inhibitor (NNRT...
(Date:9/3/2008)...ll/ -- Simcere,Pharmaceutical Group (NYSE: SCR ),...neric pharmaceuticals and manufacturer of the pate...as Endostar) in China,announced the interim resul...st of the SFDA, Simcere initiated a Phase IV clini...peutic efficacy of Endu, a modified,version of rec...
(Date:9/3/2008)...Panacea Pharmaceuticals,Inc. today announced the ...antibodies against human aspartyl (asparaginyl) be...biomarker and therapeutic target. These antibodies...setts Institute of,Technology (MIT) and Panacea ha...evelopment of human cancer diagnostics and therape...
(Date:9/3/2008)...udy in Subjects with ALS, RICHMOND, Calif., Sept....Inc. (Nasdaq: SGMO ) announced today that it has ...aluate its drug, SB-509, in subjects,with ALS, a p...which there,are limited treatment options and no c...rmulation of a plasmid,encoding a zinc finger DNA-...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5After drought ponds keep up with the Joneses 808 1After drought ponds keep up with the Joneses 808 2After drought ponds keep up with the Joneses 808 3Studies Examine Life After Weight Loss Surgery 3715 1Studies Examine Life After Weight Loss Surgery 3715 2Studies Examine Life After Weight Loss Surgery 3715 3Studies Examine Life After Weight Loss Surgery 3715 4Baxter International Third Quarter 2007 Financial Results Conference Call 3712 1James B Hawkins Appointed to IRIDEX Board of Directors 3709 1James B Hawkins Appointed to IRIDEX Board of Directors 3709 2James B Hawkins Appointed to IRIDEX Board of Directors 3709 3
...ate breaking data,presented at the American Diabet...ns showed that, when used investigationally as,ini...tion with,metformin provided significant glycemic ...54 weeks in patients with type 2,diabetes. Additio...d also showed that JANUVIA significantly improved ...
...cant Clinical Results for,SB-509 in Development fo...22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioScie...ouraging,Phase 1 clinical data from its ZFP Therap...of the American Diabetes Association,(ADA). As dis...,Neurologic Exam and Nerve Conduction Velocities i...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5
Elongated Loop, Slightly Curved; in Stainless Steel.
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
AXIOM Artis TA is part of the AXIOM family, which introduces dynamic and efficient workflow into the clinical angiography, card- angiography, and neuroradiology procedures. On the clinical, technical
AXIOM Artis FA is a universal floor-mounted angiographic C-arm system whose flexible system architecture is ideal for vascular and non-vascular diagnostics and interventions. It provides complete erg
Medicine Products: